ÂÜÀòÂÒÂ×

Elie Sidransky joined 777 Partners in 2019. Prior to 777 Partners, Mr. Sidransky started his career as an Investment Analyst at the Israel Biotech Fund, a venture capital fund that invests exclusively in Israeli related biotechnology and pharmaceutical companies with approximately $350 million in AUM.

Mr. Sidransky holds a Bachelor of Science in Material Science & Engineering from the University of Maryland College Park and a Financial Modeling and Valuation Analyst certification from the Corporate Finance Institute.